Therapy of Primary Liver Cancer

Mei Feng; Yisheng Pan; Ruirui Kong; Shaokun Shu

The Innovation (Aug 2020)

Therapy of Primary Liver Cancer

Mei Feng,
Yisheng Pan,
Ruirui Kong,
Shaokun Shu

Affiliations

Mei Feng: Translational Cancer Research Center, Peking University First Hospital, Beijing 100034, China; Department of General Surgery, Peking University First Hospital, Beijing 100034, China
Yisheng Pan: Department of General Surgery, Peking University First Hospital, Beijing 100034, China
Ruirui Kong: Translational Cancer Research Center, Peking University First Hospital, Beijing 100034, China; Corresponding author
Shaokun Shu: Translational Cancer Research Center, Peking University First Hospital, Beijing 100034, China; Department of Biomedical Engineering, Peking University, Beijing 100871, China; Peking University Cancer Hospital, Beijing 100142, China; Corresponding author

Journal volume & issue: Vol. 1, no. 2
p. 100032

Abstract

Read online

Primary liver cancer (PLC) is a fatal disease that affects millions of lives worldwide. PLC is the leading cause of cancer-related deaths and the incidence rate is predicted to rise in the coming decades. PLC can be categorized into three major histological subtypes: hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC), and combined HCC-ICC. These subtypes are distinct with respect to epidemiology, clinicopathological features, genetic alterations, and clinical managements, which are thoroughly summarized in this review. The state of treatment strategies for each subtype, including the currently approved drugs and the potential novel therapies, are also discussed.

Published in The Innovation

ISSN: 2666-6758 (Online)
Publisher: Elsevier
Country of publisher: United States
LCC subjects: Science: Science (General)
Website: https://www.cell.com/the-innovation

About the journal

Abstract

Keywords